Delphine Legoupil
Overview
Explore the profile of Delphine Legoupil including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amrane K, Le Noach P, Hemon P, Abgral R, Le Meur C, Pradier O, et al.
Melanoma Res
. 2025 Feb;
PMID: 39945603
This study aimed to evaluate the predictive value of MHC class II (MHC-II) expression by melanoma cells in a large cohort of metastatic cutaneous melanoma patients treated with immune checkpoint...
2.
Amiot M, Mortier L, Dalle S, Dereure O, Dalac S, Dutriaux C, et al.
EClinicalMedicine
. 2024 Dec;
78:102960.
PMID: 39717261
Background: Immune checkpoint inhibitors (ICIs) have demonstrated their efficacy with a 7.5-year overall survival (OS) close to 50% for advanced stages. The design of clinical trials provides for treatment until...
3.
Vitek L, Goronflot T, Dutriaux C, Deleuze A, Le Corre Y, Duval-Modeste A, et al.
Acta Derm Venereol
. 2024 Dec;
104:adv41297.
PMID: 39670438
Metastatic uveal melanoma is a rare disease with a poor prognosis. Usual treatments have not proven effective. Tebentafusp, a bispecific protein targeting melanoma cells and T lymphocytes, is the first...
4.
Le Brun I, Dalle S, Mortier L, Dereure O, Rat S, Dutriaux C, et al.
Cancer
. 2024 Dec;
131(1):e35679.
PMID: 39645590
Background: Nivolumab obtained approval in advanced melanoma (AM) with weight-adjusted dose (WAD) administration (3 mg/kg/2 weeks). In 2018, the dosage regimen was changed to flat dose (FD) administration (240 mg/2...
5.
Karine B, Mortier L, Dereure O, Dalac S, Montaudie H, Legoupil D, et al.
Br J Dermatol
. 2024 Nov;
PMID: 39605282
Background: The Checkmate 067 randomized controlled trial, published in 2015, demonstrated improved progression-free survival and numerically, although not statistically, superior overall survival for ipilimumab + nivolumab. The objective of this...
6.
Macaire C, Lefevre W, Dalac S, Montaudie H, Legoupil D, Dereure O, et al.
Melanoma Res
. 2024 Nov;
35(1):50-59.
PMID: 39527777
The link between palliative care and oncology must continue to develop, taking into account advances in treatment.Immune checkpoint inhibition (ICI) for metastatic melanoma is associated with different types of response,...
7.
Bontoux C, Badrignans M, Afach S, Sbidian E, Mboumba D, Ingen-Housz-Oro S, et al.
Br J Dermatol
. 2024 Aug;
192(1):125-134.
PMID: 39133548
Background: Mycosis fungoides (MF) usually has an indolent course. However, some patients develop more aggressive disease and few prognostic parameters have been identified. Isolated cases of pustular MF (pMF) suggest...
8.
Pavoine M, Thuillier P, Karakatsanis N, Legoupil D, Amrane K, Floch R, et al.
EJNMMI Phys
. 2023 Dec;
10(1):79.
PMID: 38062278
Background: The aim was to investigate the feasibility of a shortened dynamic whole-body (dWB) FDG-PET/CT protocol and Patlak imaging using a population-based input function (PBIF), instead of an image-derived input...
9.
Russo D, Dalle S, Dereure O, Mortier L, Dalac-Rat S, Dutriaux C, et al.
Front Oncol
. 2023 Nov;
13:1250026.
PMID: 37936607
Background: The tumor mutational burden (TMB) is high in melanomas owing to UV-induced oncogenesis. While a high TMB is a predictive biomarker of response to PD-1 inhibitors, it may be...
10.
Pottier C, Marchand A, Kervarrec T, Le Corre Y, Nardin C, Aubin F, et al.
J Am Acad Dermatol
. 2023 Jun;
89(4):824-826.
PMID: 37307995
No abstract available.